蛇足石杉内生真菌产黄青霉菌MT-40中xanthocillin类似物生物合成基因簇的挖掘及鉴定

Xanthocillin具有显著的抗菌活性,结构中含有独特的异腈基。本文通过对蛇足石杉(Huperzia serrata)内生真菌产黄青霉菌(Penicillium chrysogenum)MT-40基因组的测序分析,利用本地BLAST等生物信息学分析工具挖掘具有合成xanthocillin类似物潜力的基因簇,结合米曲霉(Aspergillus oryzae)NSAR1异源表达技术实现基因簇中关键基因的功能鉴定。结果成功从内生真菌P.chrysogenum MT-40中发现一个合成xanthocillin类似物的生物合成基因簇(命名为for),for基因簇中的关键生物合成基因forB编码的异腈基合成酶可以催化合成2-formamido-3-(4-hydroxyphenyl)acrylic acid,基因forG编码的P450酶可以催化2-formamido-3-(4-hydroxyphenyl)acrylic acid的二聚化生成xanthocillin类似物N,N′-(1,4-bis(4-hydroxyphenyl)buta-1,3-diene-2,3-diyl)diformamide。本文研究结果为进一步从真菌中发现xanthocillin类似物提供参考。     

岷江百合类萌发素蛋白基因LrGLP2的克隆及表达特性分析

类萌发素蛋白是植物中普遍存在的一类可溶性糖蛋白,在植物抗逆胁迫中起着重要作用。依据岷江百合编码GLP的EST序列设计引物,采用快速扩增cDNA末端技术,从岷江百合犯ilium regale Wilson）克隆得到一个新的GLＰt基因的全长eDNA序列,命名为LrGLP2。LrGLP2全长cDNA为921bp,含有654bp的开放阅读框,49bp5’非编码区以及218bp3’UTR,编码217个氨基酸的蛋白质。LrGLP2编码蛋白质与已知植物GLPs家族成员间的同源性和聚类分析表明LrGLP2与来源于水稻（Oryza sativa）、节节麦似egilopstauschii）、葡萄（Vitis vinifera）中的GLPs具有较高的相似性。qRT-PCR分析显示,LrGLP2在岷江百合正常生长发育的根中有一定量的表达,而在茎和叶中几乎检测不到表达量。水杨酸、茉莉酸以及H202处理均不同程度抑制LrGLP2的转录水平,但乙烯处理能明显诱导LrGLP2的表达。此外,岷江百合接种尖孢镰刀菌（Fusari—umoxysporumfsp．tiliO后,LrGLP2在接种后2h表达迅速上调,12h表达量急剧上升,至24h表达量达到最大值,之后表达量下降,可见￡rGLP2参与岷江百合对尖孢镰刀菌的防卫反应。     

供磷水平对梨砧木生长和15N-尿素吸收利用特性的影响

以一年生盆栽豆梨、川梨、木梨实生苗为试材,采用¹⁵N同位素示踪技术,研究了不同供磷水平(P₂O₅分别为0、50、100、150、200 kg·hm^-2,分别用P₀、P₁、P₂、P₃、P₄表示)对3种梨砧木生长和¹⁵N-尿素吸收、利用特性的影响.结果表明: 随着供磷水平的提高,砧木的株高、地径、干质量、根系总表面积、总根长、根尖数、根系活力、根系呼吸速率、Ndff值和氮素利用率均先升高后降低,但不同砧木升降幅度不同,且各指标出现峰值的磷水平不同.在同一磷素水平下,木梨的株高、地径、干质量均最高,川梨次之,豆梨最低,根系形态指标和根系呼吸速率呈相同规律,而Ndff值和氮素利用率表现不同.在不同磷素水平下,木梨在P₃处理各指标均达到最高水平,而川梨和豆梨分别在P₂和P₁处理各指标均达到最高水平;砧木各器官的Ndff值在不同磷水平下均以茎最高;木梨的最高氮素利用率(种植季的肥料N回收率)为9.6%、川梨为8.9%、豆梨为8.3%.以上结果表明,不同梨砧木生长和氮素吸收利用特性在不同磷水平下响应不同,生产中应根据砧木需磷特性合理施磷.     

铅对大鼠海马神经细胞H-电流特性的影响

应用全细胞膜片钳技术研究了铅对大鼠海马神经细胞H－电流特性的影响。结果表明：铅抑制了H－电流表达;降低了H－通道电压敏感性和升高了H－通道的激活电压。铅对H－电流的压抑效应有其对H－通道电压敏感性的改变,是铅损伤神经活动的一个因素之一。     

Time-dependent loss of radioimmunoassayable levels of progesterone following ambient temperature incubation of heparinized bovine blood

Plasma progesterone levels in heparinized blood collected at 10 min intervals for 8 continuous hours from four nulliparous Holstein cows on day 3 (early luteal), day 10 or 11 (mid-luteal) and day 18 or 19 of the estrous cycle were found to decline over time when blood was incubated at ambient temperature. The loss was more obvious during the mid-luteal collection period than either the day 3 or day 18 or 19 periods in all cows. This appeared to be associated more with high progesterone levels on day 10 or 11 rather than with differences in the period of the estrous cycle. There was an average decrease in progesterone levels of 3.4, 1.0 and 1.5 ng/ml between samples having the shortest and longest incubation periods on day 10 or 11, day 3 and day 18 or 19, respectively. This apparent decrease in levels of progesterone from bovine blood indicates need in the future for careful consideration concerning the handling of bovine blood collected for subsequent radioimmunoassay (RIA) of progesterone. Further work to elucidate the mechanism which is responsible for the apparent loss is also warranted.     

运动应激介导线粒体DAMP对先天性免疫的调控作用研究进展

线粒体是先天性免疫的关键调控者,具体表现为:线粒体可以通过释放多种线粒体损伤相关分子模式(damage-associated molecular patterns,DAMPs)来诱发先天性免疫应答,如线粒体DNA(mitochondrial DNA,mtDNA)、线粒体转录因子 A(mitochondrial tran...     

佐剂增强的肿瘤细胞裂解物疫苗抗小鼠H22肝癌作用

以鼠源肝癌H22全细胞裂解物为抗原,通过化学偶联白喉毒素(DT)和串联重复的T辅助表位mH-SP70407-426肽段,混合OK432(链球菌A群)制成肿瘤全细胞疫苗H22-DT-M2-OK432(HDTMOK)。治疗性免疫结果显示,疫苗激发的免疫应答对H22肿瘤起到了有效的抑制作用。为进一步提高该疫苗的抗肿瘤效果,用偶联的疫苗制备免疫刺激复合物(ISCOM),并验证其抑瘤效果。治疗性免疫结果显示,与PBS组相比,ISCOM疫苗组平均瘤重和瘤体积显著降低(P<0.01),同时有效地抑制了小鼠皮内肿瘤模型中的血管新生(P<0.01);ELISA法从血清中检测到高滴度的抗体。且与HDTMOK疫苗相比,ISCOM疫苗抑瘤作用提升显著(P<0.05)。HDTMOK能有效抑制小鼠肝癌实体瘤生长,佐剂配伍后的疫苗对H22的抑制更为显著,能够有效提升肿瘤全细胞疫苗的抗肿瘤能力。     

Predictors of Remission in Depression to Individual and Combined Treatments (PReDICT): Study Protocol for a Randomized Controlled Trial

ABSTRACT: BACKGROUND: Limited controlled data exist to guide treatment choices for clinicians caring for patients with major depressive disorder (MDD). Although many putative predictors of treatment response have been reported, most were identified through retrospective analyses of existing datasets and very few have been replicated in a manner that can impact clinical practice. One major confound in previous studies examining predictors of treatment response is the patient's treatment history, which may affect both the predictor of interest and treatment outcomes. Moreover, prior treatment history provides an important source of selection bias, thereby limiting generalizability. Consequently, we initiated a randomized clinical trial designed to identify factors that moderate response to three treatments for MDD among patients never treated previously for the condition. METHODS: Treatment-naive adults aged 18-65 years with moderate-to-severe, non-psychotic MDD are randomized equally to one of three 12-week treatment arms: 1) cognitive behavior therapy (CBT, 16 sessions), 2) duloxetine (30-60 mg/d), or 3) escitalopram (10-20 mg/d). Prior to randomization, patients undergo multiple assessments, including resting state functional magnetic resonance imaging (fMRI), immune markers, DNA and gene expression products, and dexamethasone-corticotropin releasing hormone (Dex/CRH) testing. Prior to or shortly after randomization, patients also complete a comprehensive personality assessment. Repeat assessment of the biological measures (fMRI, immune markers, and gene expression products) occur at an early time-point in treatment, and upon completion of 12-week treatment, when a a second Dex/CRH test is also conducted, Patients remitting by the end of this acute treatment phase are then eligible to enter a 21-month follow-up phase, with quarterly visits to monitor for recurrence. Non-remitters are offered augmentation treatment for a second 12-week course of treatment, during which they receive a combination of CBT and antidepressant medication. Predictors of the primary outcome, remission, will be identified for overall and treatment-specific effects, and a statistical model incorporating multiple predictors will be developed to predict outcomes. DISCUSSION: The PReDICT study's evaluation of biological, psychological, and clinical factors that may differentially impact treatment outcomes represents a sizeable step toward developing personalized treatments for MDD. Identified predictors should help guide the selection of initial treatments, and identify those patients most vulnerable to recurrence, who thus warrant maintenance or combination treatments to achieve and maintain wellness.